28-day survival rates of patients ingesting different volumes of 20% liquid paraquat (w/v).

<p>Note: XBJ, <i>Xuebijing</i> injection.</p><p>28-day survival rates of patients ingesting different volumes of 20% liquid paraquat (w/v).</p

Baseline characteristics.

<p>Note: XBJ, <i>Xuebijing</i> injection; BMI, Body mass index; APACHE II, Acute Physiology and Chronic Health Evaluation II; NS, no significance.</p><p>Baseline characteristics.</p

Vital organ functions in both groups during XBJ treatment.

<p>Note: XBJ, <i>Xuebijing</i> injection; ALT, alanine aminotransferase; TnT, troponin T.</p><p>*<i>P</i><0.05 XBJ group <i>vs</i>. control group;</p><p>**<i>P</i><0.05 control group on Day 3 <i>vs</i>. control group on Day 1.</p><p>Vital organ functions in both groups during XBJ treatment.</p

Significant risk factors for mortality among patients with paraquat poisoning.

<p>Note: Adjusted for covariates including age, gender, body mass index, time to gastric lavage, APACHE II scores, volume of oral paraquat, and time to haemoperfusion. APACHE II, Acute Physiology and Chronic Health Evaluation II; BMI, body mass index; CI, confidence interval.</p><p>Significant risk factors for mortality among patients with paraquat poisoning.</p

Fingerprint chromatograph of XBJ.

<p>Fingerprint chromatograph of XBJ.</p

Kaplan-Meier Survival Curves for (A) all patients and (B) patients ingesting 10–30 ml of 20% liquid paraquat (w/v).

<p>The differences in survival curves between the control and XBJ groups were not significant in A (<i>P</i> = 0.06), but significant in B (<i>P</i> = 0.02), as compared using a Log rank test. XBJ, <i>Xuebijing</i> injection.</p